BioMerieux (STU:EYWN) Short Interest


STU:EYWN BioMerieux SA STU:EYWN
85 GF Score
Price €69.70
GF Value €109.65
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:EYWN vs TMO, DHR, IDXX: Short Interest Comparison

For the Diagnostics & Research subindustry, BioMerieux's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMerieux Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Short Interest distribution charts can be found below:

* The bar in red indicates where BioMerieux's Short Interest falls into.


STU:EYWN
85GF Score
BioMerieux SA STU:EYWN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (STU:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €69.70 is trading 36.4% below its estimated GF Value™ of €109.65. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for STU:EYWN:

  • Short Interest:
  • GF Value™: €109.65 vs. price of €69.70 (36.4% below fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the STU:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
85GF Score

Get the complete analysis for STU:EYWN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.70
Price
€109.65
GF Value